StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.97−0.03 (-3.47%)

Close on Nov 18, 2026Market cap $134.14MP/E –Yield –

ALX Oncology r&d expenses

Research and development expenses are spending on new products and technology.

ALX Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $61.83M, down 32.7% year over year. For fiscal 2025 it was $77.00M, down 33.8% from the year before. The highest annual figure on record is $141.80M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$77.00M-33.8%
FY2024Dec 31, 2024$116.37M-17.9%
FY2023Dec 31, 2023$141.80M+44.1%
FY2022Dec 31, 2022$98.40M+63.5%
FY2021Dec 31, 2021$60.17M+107.8%
FY2020Dec 31, 2020$28.96M+77.6%
FY2019Dec 31, 2019$16.31M+44.7%
FY2018Dec 31, 2018$11.27M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.14M-27.1%
Q1 FY2026Mar 31, 2026$13.61M-43.0%
Q4 FY2025Dec 31, 2025$17.65M-25.0%
Q3 FY2025Sep 30, 2025$17.44M-34.1%
Q2 FY2025Jun 30, 2025$18.02M-48.0%
Q1 FY2025Mar 31, 2025$23.89M-24.7%
Q4 FY2024Dec 31, 2024$23.53M-43.7%
Q3 FY2024Sep 30, 2024$26.47M-42.2%
Q2 FY2024Jun 30, 2024$34.65M+17.5%
Q1 FY2024Mar 31, 2024$31.72M+28.1%
Q4 FY2023Dec 31, 2023$41.78M+65.8%
Q3 FY2023Sep 30, 2023$45.77M+55.8%
Q2 FY2023Jun 30, 2023$29.48M+10.2%
Q1 FY2023Mar 31, 2023$24.76M+45.0%
Q4 FY2022Dec 31, 2022$25.20M+20.6%
Q3 FY2022Sep 30, 2022$29.38M+61.3%
Q2 FY2022Jun 30, 2022$26.75M+138.5%
Q1 FY2022Mar 31, 2022$17.07M+73.3%
Q4 FY2021Dec 31, 2021$20.89M+72.1%
Q3 FY2021Sep 30, 2021$18.21M+241.9%
Q2 FY2021Jun 30, 2021$11.21M+46.3%
Q1 FY2021Mar 31, 2021$9.85M+157.3%
Q4 FY2020Dec 31, 2020$12.14M+80.3%
Q3 FY2020Sep 30, 2020$5.33M+141.1%
Q2 FY2020Jun 30, 2020$7.66M+111.2%
Q1 FY2020Mar 31, 2020$3.83M–
Q4 FY2019Dec 31, 2019$6.74M–
Q3 FY2019Sep 30, 2019$2.21M–
Q2 FY2019Jun 30, 2019$3.63M–

More ALX Oncology figures

See a number that looks wrong?